Taylor Maritime fishes for 'economies of scale' from Grindrod deal
Taylor Maritime has aligned management of its vessels with Grindrod Shipping, which it acquired last year, and overhauled its debt facilities.
Investment company news brought to you by Citywire Financial Publishers Limited and Quoted Data by Marten & Co.
Taylor Maritime has aligned management of its vessels with Grindrod Shipping, which it acquired last year, and overhauled its debt facilities.
As lending markets become expensive the £352m Schroder Japan trust wants to use contracts for difference (CFDs) to borrow cheaply and boost returns ahead of a performance deadline next year.
Investment manager AEW continues to offload bad properties from the suspended homeless accommodation provider as it looks to stablise the suspended portfolio.
Andrew Sutch, chair of Hipgnosis Songs Fund, agrees to leave as royalties fund sets out a timetable to sack its fund manager if the share price does not re-rate in a year's time.
JPMorgan Emerging Markets trust has cut its fees after it avoided the falls it index suffered in its last financial year.
Debt-laden Triple Point digital infrastructure fund starts a formal consultation with shareholders to discuss its future dividend policy and direction as a company.
Manager James Armstrong said the 8.6p-per-share, full-year dividend, which was 0.2p above target, and the long-term visibility of earnings should narrow the discount.
Suspended renewables fund picks manager of rival Octopus Renewables Infrastructure to run its portfolio until next April after sacking ThomasLloyd Global Asset Management.
The £33m trust said UK commercial property market conditions had made its managed wind-down difficult as high interest rates and high inflation impacted property transaction volumes.
The infrastructure trust has spent almost all of its cash resources and will be cautious about future investment as it weighs up its other commitments.
The infrastructure trust has spent almost all of its cash resources and will be cautious about future investment as it weighs up its other commitments.
Arix Bioscience chief executive Robert Lyne departs midway through a strategic review with the shares trading at a 38% discount.
Developed by Moore-Wilson